CIK 0001434316
- Non-accelerated filer
- Smaller reporting company
FATE THERAPEUTICS INC
Sign in to watch- Ticker
- FATE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 651311552
- Phone
- +1 858-875-1803
- Business address
- 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA, 92131
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $13,525
- in 1 filing
Net −$13,525. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-01-10 | Wolchko J Scott President and CEO | Sale | −20,894 | $47.17 | $986K | 446,213 |
| 2022-01-10 | Wolchko J Scott President and CEO | Sale | −101 | $47.72 | $5K | 446,112 |
| 2022-01-10 | TAHL CINDY General Counsel and Secretary | Sale | −7,095 | $46.37 | $329K | 161,911 |
| 2022-01-10 | TAHL CINDY General Counsel and Secretary | Sale | −643 | $47.15 | $30K | 161,268 |
| 2022-01-10 | Valamehr Bahram Chief R&D Officer | Sale | −5,245 | $46.33 | $243K | 151,453 |
| 2022-01-10 | Valamehr Bahram Chief R&D Officer | Sale | −351 | $47.17 | $17K | 151,102 |
| 2022-01-03 | TAHL CINDY General Counsel and Secretary | Option exercise | +50,000 | $6.55 | $328K | 219,006 |
| 2022-01-03 | TAHL CINDY General Counsel and Secretary | Sale | −4,427 | $57.76 | $256K | 214,579 |
| 2022-01-03 | TAHL CINDY General Counsel and Secretary | Sale | −16,900 | $58.84 | $994K | 197,679 |
| 2022-01-03 | TAHL CINDY General Counsel and Secretary | Sale | −27,812 | $59.86 | $1.7M | 169,867 |
| 2022-01-03 | TAHL CINDY General Counsel and Secretary | Sale | −861 | $60.31 | $52K | 169,006 |
| 2022-01-03 | TAHL CINDY General Counsel and Secretary | Option exercise · Stock Option (Right to Buy) | −50,000 | 66,643 | ||
| 2021-12-20 | Dulac Edward J III Chief Financial Officer | Option exercise | +14,437 | $35.52 | $513K | 126,381 |
| 2021-12-20 | Dulac Edward J III Chief Financial Officer | Sale | −15,977 | $60.00 | $959K | 110,404 |
| 2021-12-20 | Dulac Edward J III Chief Financial Officer | Option exercise · Stock Option (Right to Buy) | −14,437 | 128,238 | ||
| 2021-12-13 | Valamehr Bahram Chief R&D Officer | Option exercise | +25,000 | $2.73 | $68K | 181,698 |
| 2021-12-13 | Valamehr Bahram Chief R&D Officer | Sale | −2,100 | $45.68 | $96K | 179,598 |
| 2021-12-13 | Valamehr Bahram Chief R&D Officer | Sale | −7,018 | $46.72 | $328K | 172,580 |
| 2021-12-13 | Valamehr Bahram Chief R&D Officer | Sale | −6,564 | $47.61 | $313K | 166,016 |
| 2021-12-13 | Valamehr Bahram Chief R&D Officer | Sale | −7,718 | $48.75 | $376K | 158,298 |
Page 14 of 26 · 503 trades